Leading Neurologist Remains Skeptical In Run-Up To NMT’s MIST Trial Results

The soon-to-be-released results of NMT's patent foramen ovale (PFO) closure trial will need to demonstrate a 30% difference in frequency of migraine between the treatment group and the placebo group to be clinically relevant, according to a leading neurologist